Brought to you by 
Lab21 gets rights to THEROS test from bioTheranostics
27 Apr 2021
Executive Summary
BioTheranostics, a molecular testing division of bioMerieux and the Merieux Alliance, has granted Lab21 (UK diagnostics and testing services start-up formerly known as Newmarket Laboratories) rights to sell its THEROS CancerTYPE ID (CTID) test for two years in the UK, Ireland, and the Middle East.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lab21 gets rights to THEROS test from bioTheranostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice